Drug Trial Radar · NCT07920159
Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Sep 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Anhui Provincial HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with advanced high-grade serous ovarian cancer who underwent primary cytoreductive surgery and received adjuvant chemotherapy with paclitaxel plus carboplatin were included. CA125 levels were dynamically monitored within 100 days post-surgery, and the KELIM value was calculated to identify patients at high risk of recurrence with a KELIM \< 1.
Conditions
- High-grade Serous Ovarian Cancer
Interventions
SuvemcitugDrug
The enrolled patients received sutilitaxel 2 mg/kg, administered once every 3 weeks, in combination with the Paclitaxel combined with Carboplatin regimen for intensified treatment from Cycle 4 to Cycle 6, and then received sutilitaxel monotherapy for maintenance treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From the date of definitive surgery to the first documented disease recurrence or death from any cause, whichever occurs first, assessed up to 36 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.